LIVZON GROUP(SZ:000513)2023-06-09 08:41Financial Performance - In 2022, the company achieved a revenue of CNY 12.63 billion, a year-on-year increase of 4.69% [1] - The net profit attributable to shareholders was CNY 1.909 billion, up 7.53% year-on-year [1] - In Q1 2023, the company reported a revenue of CNY 3.413 billion, a decrease of 1.90% year-on-year [1] - The net profit attributable to shareholders for Q1 2023 was CNY 582 million, an increase of 5.17% year-on-year [1] Revenue Breakdown by Segment - Chemical preparations generated revenue of CNY 7 billion, a slight increase of 0.02% year-on-year [1] - Raw materials and intermediates achieved revenue of CNY 3.138 billion, a year-on-year increase of 7.89% [1] - Traditional Chinese medicine preparations reported revenue of CNY 1.254 billion, up 17.07% year-on-year [1] - Diagnostic reagents and equipment generated revenue of CNY 724 million, remaining stable [1] - The newly added biopharmaceutical segment achieved revenue of CNY 408 million, a significant increase of 80.94% year-on-year [1] Market Challenges and Outlook - Prescription drug sales faced limitations in Q1 2023, particularly in chemical drugs, which saw a year-on-year decline of 20.95% [2] - The decline was attributed to the impact of inventory buildup during the Spring Festival and the slow recovery of hospital terminals [2] - The company remains optimistic about the sales outlook for 2023, expecting recovery in prescription drug sales from March onwards [2] Product Development and Innovation - The company is advancing the clinical trials for semaglutide, with plans to complete enrollment in 2023 and aim for approval in 2025 [3] - New indications for existing products, such as the injection of esomeprazole sodium, have been approved, expanding market applications [4] - The company is focusing on the development of traditional Chinese medicine products, with plans to enhance R&D capabilities in this area [5] Strategic Initiatives - The establishment of a modernized Chinese medicine technology company aims to innovate and develop new products in the traditional medicine sector [5] - The company is also expanding into the pet medication market, with two products already approved and more in development [6] - Continuous efforts are being made to promote new products and adapt to market changes, ensuring stable growth in revenue [5]